Table of Content

Strategic Imperatives
Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Inhaled Therapeutics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Growth Opportunity Analysis
Scope of Analysis
The Need for Inhalation Biologics Formulation
Inhalation Drug Delivery—Introduction
Segmentation—Formulations for Drug Inhalation
Pros and Cons of Formulation and Drug Delivery Systems for Inhalation
Examples of Novel Formulations and Drug Delivery System for Inhalable Biologics
Promising Inhalation Therapy—Advantages of Inhalational Monoclonal Antibodies (mAbs) and Vaccines
Growth Drivers
Growth Restraints
Industry Assessment and Analysis
Pipeline Analysis of Inhaled Vaccines and mAbs
Vaccines and mAbs under Clinical Development
Primary Technologies—AttenuBlock Platform Technology (Codon Deoptimization for Live Attenuated Vaccine Candidates)
Primary Technologies—Nanoemulsion Platform (Intranasal Adjuvant Technology)
Innovation Ecosystem
R&D Trends
Collaboration and Partnership Trends
Funding and Investment Analysis
Patent Analysis
Future Roadmap
Growth Opportunity Universe
Growth Opportunity 1: Drug Repurposing Using Nanotechnology to Produce a Nebulizer Solution
Growth Opportunity 1: Drug Repurposing Using Nanotechnology to Produce a Nebulizer Solution (continued)
Growth Opportunity 2: Partnering with a CDMO that Offers End-to-end Services
Growth Opportunity 2: Partnering with a CDMO that Offers End-to-end Services (continued)
Growth Opportunity 3: Gene-based Antibody Delivery for Safe Inhaled Administration
Growth Opportunity 3: Gene-based Antibody Delivery for Safe Inhaled Administration (continued)
Legal Disclaimer